medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (4)


Liver iron concentration is not raised in patients with dysmetabolic hyperferritinemia

Castiella A, Zapata E, Zubiaurre L, Iribarren A, Alústiza JM, Otazua P, Salvador E, Emparanza JI

Idioma: Ingles.
Referencias bibliográficas: 23
Paginas: 540-544
Archivo PDF: 145.54 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Alkerwi A, Donneau AF, Sauvageor N, Lair ML, Scheen A, Albert A, Guillaume Ml. Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study. BMC Public Health 2011; 11: 4.

  2. McCullough AJ. The epidemiology of the metabolic syndrome in the USA. J Dig Dis 2011; 12: 333-40.

  3. Chen LY, Chang SD, Sreenivasan GM, Tsang PW, Broady RC, Li CH, Zypchen LN. Dysmetabolic hyperferritinemia is associated with normal transferrin saturation, mild hepatic iron overload, and elevated hepcidin. Ann Hematol 2011; 90: 139-43.

  4. Brudevold R, Hole T, Hammerstrom J. Hyperferritinemia is associated with insuline resistence and fatty liver in patients without iron overload. PLoS One 2008; 3: e347.

  5. Castiella A, Alústiza JM, Zapata E, Emparanza JI, Otazua P, Zubiaurre L, Aguirre A. Mild iron overload in dysmetabolic hyperferritinemia: MRI may overestimate the liver iron concentration values. Ann Hematol 2012; 91: 961.

  6. Castiella A, Zapata E, Zubiaurre L, Alustiza JM, De Juan MD, Iribarren A, Emparanza JI, et al. Impact of H63D mutations, magnetic resonance and metabolic syndrome among outpatient referrals for elevated serum ferritin in the Basque Country. Ann Hepatol 2015; 14: 333-9.

  7. Alustiza JM, Artetxe J, Castiella A, Aguirre C, Emparanza JI, Otazua P, Garcia-Bengoechea M, et al. MR quantification of hepatic iron concentration. Radiology 2004; 230: 479-84.

  8. Licata A, Nebbia ME, Cabibbo G, Lo Iacono G, Barbaria F, Brucato V, Alessi N, et al. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 2009; 15: 2132-8.

  9. Alústiza JM, Castiella A. Liver fat and iron at in-phase and opposed-phase MR imaging. Radiology 2008; 246: 641.

  10. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new world wide definition. Lancet 2005; 366: 1059-62.

  11. Mendler MH, Turlin B, Moirand R, Jouanolle A, Sapey T, Guyader D, Le Gall, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.

  12. Riva A, Trombini P, Mariani R, Salvioni A, Coletti S, Bonfadini S, Paolini V, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 2008; 14: 4745-52.

  13. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 2448-55.

  14. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. J Hepatol 2011; 55: 920-32.

  15. Jézéquel C, Lainé F, Laviolle B, Kiani A, Bardou-Jacquet E, Deugnier Y. Both hepatic and body iron stores are increased in dysmetabolic iron overload syndrome. A casecontrol study. PLoS ONE 2015; 10: e0128530.

  16. Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, Pulixi EA, et al. A randomized trial of iron depletion in patients with non-alcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002-10.

  17. Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, et al. The impact of phlebotomy in non-alcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology 2015; 61: 1555-64.

  18. Brissot P, de Bels F. Current approaches to the manegement of hemochromatosis. Hematology Am Soc Hematol Educ Program 2006: 36-41.

  19. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, et al. Prevalence of body iron excess in the metabolic syndrome. Diab Care 2005; 28: 2061-3.

  20. Waeber G, Vollenweider P, Maeques-Vidal PM. Dysmetabolic hyperferritinemia: a new target for treatment? Rev Med Suisse 2013; 9: 2002-7.

  21. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357-62.

  22. Castiella A, Alustiza JM, Emparanza JI, Zapata EM, Costero B, Diez MI. Liver iron concentration quantification by MRI: are recommended protocols accurate enough for clinical practice? Eur Radiol 2011; 21: 137-41.

  23. Freixenet N, Vilardell C, Llauradó G, Giménez-Palop O, Berlanga E, Gutiérrez C, Caixàs A, et al. Men with hyperferritinemia and diabetes in the Mediterranean area do not have a higher iron overload than those without diabetes. Diabetes Res Clin Pract 2011; 91: e33-e36.




2020     |     www.medigraphic.com